---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001461"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:45:34.833398+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tivic Health CEO Jennifer Ernst resigns; Michael Handley appointed CEO to lead biopharma pivot

## Summary
- CEO Jennifer Ernst resigned March 2, 2026; board departure effective March 5; separation includes $325K cash severance, COBRA, equity vesting, and $50K restricted stock.
- Michael Handley appointed CEO and board member effective March 3; previously COO and President of Tivic Biopharma since February 2025.
- Handley brings over 20 years life sciences experience; led commercialization of 17 products, worked at Amgen and Genentech.
- Company shifts strategic focus to late-stage immunotherapies and biomanufacturing subsidiary Velocity Bioworks; highlights Entolimod as key asset.
- No dispute or disagreement with Ernst's resignation; Handley's existing employment agreement unchanged from February 2025.

## SEC filing metadata
- accession: 0001683168-26-001461
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826001461/0001683168-26-001461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826001461/tivic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001461
- JSON: https://secwatch.observer/filing/0001683168-26-001461.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.